Lisata Therapeutics, Inc.
LSTA
$2.50
-$0.03-1.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.11% | -3.42% | -0.43% | 8.13% | -21.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.59% | -11.42% | -1.26% | -10.53% | -19.67% |
| Operating Income | 11.86% | 11.42% | 17.86% | 10.53% | 19.67% |
| Income Before Tax | 7.63% | 8.28% | 14.07% | 6.29% | 20.65% |
| Income Tax Expenses | -- | -20.55% | -- | -- | -- |
| Earnings from Continuing Operations | 7.63% | 12.53% | 14.07% | 6.29% | -25.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.63% | 12.53% | 14.07% | 6.29% | -25.25% |
| EBIT | 11.86% | 11.42% | 17.86% | 10.53% | 19.67% |
| EBITDA | 11.94% | 11.46% | 17.90% | 10.53% | 19.77% |
| EPS Basic | 10.82% | 15.66% | 16.66% | 8.31% | -20.91% |
| Normalized Basic EPS | 10.83% | 10.25% | 16.18% | 8.32% | 23.38% |
| EPS Diluted | 10.82% | 15.66% | 16.66% | 8.31% | -20.91% |
| Normalized Diluted EPS | 10.83% | 10.25% | 16.18% | 8.32% | 23.38% |
| Average Basic Shares Outstanding | 3.57% | 3.71% | 3.11% | 2.21% | 3.58% |
| Average Diluted Shares Outstanding | 3.57% | 3.71% | 3.11% | 2.21% | 3.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |